P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
Bibliographic record
Abstract
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: There are many considerations when selecting treatment for relapsed MM including treatment-related (safety and response rates) and patient-related (tolerability and convenience) factors. Triplet-based regimens that combine active classes of drugs (PI, IMiD and CD38 antibodies) are preferred. Updated results from the IKEMA study reported a PFS of 35.7 months in patients receiving isatuximab, twice weekly high-dose carfilzomib(56mg/m2) and dex(Isa-Kd). Aims: The aim of this study was to assess the safety and efficacy of Isa-Kd utilizing once weekly high-dose K (70 mg/m2) in patients with relapsed multiple myeloma. Methods: Eligible pts had RRMM, received at least 1 but no more than 3 prior lines of therapy, had no prior exposure to CD38 antibodies and could have received K but could not be K refractory. Patients were required to have adequate blood counts and organ function. Pts received standard dose Isa 10 mg/kg IV Qwk x 4 doses then ISA 10 mg/kg IV every other week, K 20 mg/m2 on C1D1 then K 70 mg/m2 C1D8 and 15 and on D1, 8, 15 in subsequent 28-day cycles, and dex 40 mg Qwk. This study was developed in cooperation with the Multiple Myeloma Research Consortium and 5 sites are actively enrolling subjects. Results: As of January 31, 2023; 33 patients have been enrolled, median follow-up is 9 mo (range, 2.0–27). Median age is 64 y (range, 35–83; 12pts 70+); 20M, 13F; 34% of pts had high cytogenetic risk and an additional 22% had isolated 1q21 gain/amp. Pts had a median of 1 prior LOT (range, 1–3): 100% IMiD and PI exposed; 43% Len refractory. The most common hematologic toxicity was thrombocytopenia (21%; 15% Gr2/3). The most common non-hematologic adverse events (incidence >20%) were hypertension (HTN) (48%: 18% Gr3), infection (45%, 3% Gr3), infusion reactions (39%; all Gr 1/2), fatigue (33%), dyspnea (27%), insomnia (21%) and ALT elevation (21%). Cardiovascular AE’s were seen in 3 patients (Gr3 MI, Gr2 DVT, Gr2 pulmonary edema). The ORR was 87.5% (sCR/CR 2, VGPR 18, PR 8; 62.5% ≥VGPR). Median time to first response was 28 days (range 28-NR); median DOR was not reached and treatment is on-going in 24/33. No patients discontinued therapy due to an adverse event. Summary/Conclusion: The combination of Isa + weekly Kd appears safe with manageable side effects. Rapid responses have been seen with an ORR of 87.55% (62.5% achieving ≥VGPR) and responses deepening over time. No unexpected safety signals have been noted and these early results support the use of Isa-with weekly Kd in patients with relapsed MM. Keywords: Multiple myeloma, Myeloma
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".